Patents Assigned to Gilead Sciences, Inc.
-
Patent number: 11912686Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).Type: GrantFiled: December 6, 2022Date of Patent: February 27, 2024Assignee: Gilead Sciences, Inc.Inventors: Brian P. Bestvater, Julie Farand, Doris T. Tang, Kin S. Yang
-
Patent number: 11905299Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.Type: GrantFiled: May 11, 2021Date of Patent: February 20, 2024Assignee: Gilead Sciences, Inc.Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
-
Patent number: 11903953Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.Type: GrantFiled: March 30, 2023Date of Patent: February 20, 2024Assignee: Gilead Sciences, Inc.Inventor: Tomas Cihlar
-
Patent number: 11897878Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: November 9, 2021Date of Patent: February 13, 2024Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C Yeung, Jeff Zablocki
-
Patent number: 11897862Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.Type: GrantFiled: April 7, 2023Date of Patent: February 13, 2024Assignee: Gilead Sciences, Inc.Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
-
Patent number: 11896648Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.Type: GrantFiled: October 20, 2021Date of Patent: February 13, 2024Assignee: GILEAD SCIENCES, INC.Inventors: Manuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
-
Patent number: 11897892Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.Type: GrantFiled: February 3, 2023Date of Patent: February 13, 2024Assignee: Gilead Sciences, Inc.Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
-
Patent number: 11883397Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: November 22, 2021Date of Patent: January 30, 2024Assignee: Gilead Sciences, Inc.Inventors: Manoj C. Desai, Mingzhe Ji, Haolun Jin, Hyung-Jung Pyun, Teresa Alejandra Trejo Martin
-
Patent number: 11878965Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: GrantFiled: December 21, 2021Date of Patent: January 23, 2024Assignee: Gilead Sciences, Inc.Inventors: Daniel H. Byun, Zhenhong R. Cai, Eda Y. Canales, Laurent P. Debien, Timothy R. Hansen, Richard Huang, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Ryan McFadden, Michael L. Mitchell, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Joshua J. Van Veldhuizen, Lianhong Xu
-
Patent number: 11858918Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: April 19, 2022Date of Patent: January 2, 2024Assignee: GILEAD SCIENCES, INC.Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
-
Patent number: 11851438Abstract: 1?-Cyano nucleoside analogs of Formula I and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: March 6, 2023Date of Patent: December 26, 2023Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
-
Patent number: 11851419Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.Type: GrantFiled: November 18, 2021Date of Patent: December 26, 2023Assignee: Gilead Sciences, Inc.Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
-
Patent number: 11845739Abstract: The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yOpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.Type: GrantFiled: January 26, 2022Date of Patent: December 19, 2023Assignee: Gilead Sciences, Inc.Inventor: Bing Shi
-
Patent number: 11845737Abstract: Disclosed are syntheses of a Cot (cancer Osaka thyroid) inhibitor, which has the following formula:Type: GrantFiled: March 31, 2021Date of Patent: December 19, 2023Assignee: Gilead Sciences, Inc.Inventors: Kevin M. Allan, Lina Chan, Andrei Chtchemelinine, Jeffrey T. Deignan, Kassibla E. Dempah, Kelly J. Eberle, Danielle M. Elfgren, Timothy G. Elford, Kevin D. Haggerty, Jesse W. Li, Tianmin Niu, Andrew C. Stevens, Ana F. Voica, Kevin S. Williamson, Boran Xu, Guojun Yu
-
Patent number: 11845755Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: March 6, 2023Date of Patent: December 19, 2023Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
-
Patent number: 11845723Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.Type: GrantFiled: December 18, 2020Date of Patent: December 19, 2023Assignee: Gilead Sciences, Inc.Inventors: Masaaki Sawa, Mai Arai, Ryoko Nakai, Hirokazu Matsumoto, Catherine Pugh, Eric Hu, Juan Guerrero, Jesse Jacobsen, Jonathan William Medley, Jie Xu, Latesh Lad, Leena Patel, Michael Graupe, Qingming Zhu, Stephen Holmbo, Tetsuya Kobayashi, Will Watkins, Yasamin Moazami, Suet C. Yeung, Julian A. Codelli, Heath A. Weaver
-
Patent number: 11833143Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfony)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.Type: GrantFiled: January 26, 2022Date of Patent: December 5, 2023Assignee: Gilead Sciences, Inc.Inventors: Travis Lee Houston, Bing Shi
-
Patent number: 11833150Abstract: The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.Type: GrantFiled: February 27, 2020Date of Patent: December 5, 2023Assignee: Gilead Sciences, Inc.Inventors: Jamie Geier Bates, David Gordon Clarkson Breckenridge, John T. Liles
-
Patent number: 11827609Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.Type: GrantFiled: August 11, 2021Date of Patent: November 28, 2023Assignee: Gilead Sciences, Inc.Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
-
Patent number: 11827662Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.Type: GrantFiled: April 7, 2022Date of Patent: November 28, 2023Assignee: Gilead Sciences, Inc.Inventors: Eda Y. Canales, Manoj C. Desai, Eric Gorman, Jiayao Li, Roland D. Saito, James G. Taylor, Nathan E. Wright